Nanotherapeutic strategies for mitigating sepsis-induced multiorgan dysfunctions

Area of Science:

• Biomedical Engineering
• Nanomedicine
• Immunology

Background:

• Sepsis causes significant morbidity and mortality due to uncontrolled inflammation and organ failure.
• Current sepsis treatments face challenges with drug delivery, stability, and toxicity.
• Nanotechnology presents a promising avenue for overcoming these therapeutic limitations.

Purpose of the Study:

• To review advancements in nano-enabled therapeutic strategies for sepsis-induced organ injuries.
• To discuss nanocarrier engineering, targeting mechanisms, and delivery platforms for sepsis.
• To highlight translational progress and barriers for clinical adoption of nanotherapies.

Main Methods:

• Review of current literature on nanotechnology applications in sepsis treatment.
• Analysis of various nanocarrier systems (liposomes, nanoparticles, etc.) for sepsis.
• Examination of organ-targeting and stimuli-responsive nanosystems.

Main Results:

• Nanocarriers improve drug stability, bioavailability, and targeted delivery to organs affected by sepsis.
• Engineered nanosystems can modulate immune responses, reduce inflammation, and scavenge reactive oxygen species.
• Organ-targeted and stimuli-responsive nanocarriers show potential for improved therapeutic index and reduced side effects.

Conclusions:

• Nanotechnology offers a transformative approach to treating sepsis and associated organ failure.
• Nano-enabled strategies can effectively target sepsis-induced organ injuries, offering improved treatment paradigms.
• Further research and clinical translation are needed to overcome barriers to widespread adoption.